Lymphocyte Subpopulations and Tumor Necrosis Factor During Interferon-α 2b and Interleukin-2 Therapy in Patients with Metastasized Renal Cell Cancer
Treatment of patients with metastasized renal cell cancer with interferon-α2b (IFN-α2b) and interleukin-2 (IL-2) initially led to a drop in the total lymphocyte count and in all lymphocyte subpopulations with the exception of CD-19-positive cells. Upon termination of therapy, there was an excessive increase in all lymphocyte subpopulations. No correlation between the kinetics of the lymphocyte subpopulations and the clinical outcome of the patient was demonstrated. Significant stimulation of tumor necrosis factor-α (TNF-α) as a result of the treatment was not detected. This may indicate that stimulation of TNF-α by IL-2 is not an important effector mechanism.
KeywordsRenal Cell Carcinoma Lymphocyte Subpopulation Advanced Renal Cell Carcinoma Total Lymphocyte Count Human Renal Cancer Cell
Unable to display preview. Download preview PDF.
- 1.Ackermann R (1988) Immunologische Aspekte in der Behandlung des Nierenkarzinoms. In: Staehler G (ed) Das Nierenkarzinom. Springer, Berlin Heidelberg New York Tokyo, S 104–114.Google Scholar
- 4.Bono AV (1986) Steroid hormones and hormonal treatment in renal cell carcinoma. In: DeKernion JB, Pavone Macaluso M (eds) Tumors of the kidney, vol 13. Williams & Wilkins, Baltimore, pp 205–227.Google Scholar
- 6.DeKernion JB (1986) Treatment of advanced renal cell carcinoma. Traditional methods and innovative approaches. J Urol 130:2–7.Google Scholar
- 11.Gumlo BT et al (1988) Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine activated killer cells. Cancer Res 48:5864–5867.Google Scholar
- 13.Kriegmair M, Hofstetter A (1989) Interferontherapie in der Urologie. Urologe [A] 28:116–121.Google Scholar
- 18.Neidhard JA et al (1984) Interferon-α therapy of renal cancer. Cancer Res 44:4140–4143.Google Scholar